Bristol Myers Squibb Company $BMY Shares Acquired by Rafferty Asset Management LLC

Rafferty Asset Management LLC lifted its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 4.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 230,529 shares of the biopharmaceutical company’s stock after purchasing an additional 10,678 shares during the period. Rafferty Asset Management LLC’s holdings in Bristol Myers Squibb were worth $10,397,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Wealthedge Investment Advisors LLC lifted its holdings in Bristol Myers Squibb by 16.0% during the 3rd quarter. Wealthedge Investment Advisors LLC now owns 112,152 shares of the biopharmaceutical company’s stock worth $5,058,000 after buying an additional 15,466 shares during the last quarter. Harvest Portfolios Group Inc. lifted its stake in Bristol Myers Squibb by 17.2% during the third quarter. Harvest Portfolios Group Inc. now owns 1,327,460 shares of the biopharmaceutical company’s stock worth $59,868,000 after purchasing an additional 195,091 shares during the last quarter. Quantbot Technologies LP boosted its holdings in Bristol Myers Squibb by 248.5% in the third quarter. Quantbot Technologies LP now owns 496,871 shares of the biopharmaceutical company’s stock valued at $22,409,000 after purchasing an additional 354,309 shares in the last quarter. Caitlin John LLC increased its stake in Bristol Myers Squibb by 44.4% in the third quarter. Caitlin John LLC now owns 11,268 shares of the biopharmaceutical company’s stock valued at $508,000 after purchasing an additional 3,462 shares during the last quarter. Finally, Andra AP fonden raised its holdings in Bristol Myers Squibb by 65.1% during the third quarter. Andra AP fonden now owns 1,176,900 shares of the biopharmaceutical company’s stock worth $53,078,000 after purchasing an additional 463,991 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Guggenheim restated a “buy” rating and issued a $72.00 target price (up from $62.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Cantor Fitzgerald restated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Monday, November 24th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 3rd. Piper Sandler reissued an “overweight” rating and issued a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Finally, UBS Group upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and raised their price target for the stock from $46.00 to $65.00 in a research note on Wednesday, January 7th. Nine equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $60.71.

Bristol Myers Squibb Price Performance

Shares of BMY opened at $62.23 on Monday. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $63.33. The firm has a 50-day simple moving average of $56.98 and a 200-day simple moving average of $50.57. The company has a market capitalization of $126.74 billion, a price-to-earnings ratio of 18.04, a price-to-earnings-growth ratio of 0.18 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. During the same period in the prior year, the company earned $1.67 earnings per share. The firm’s revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities research analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Friday, January 2nd were issued a dividend of $0.63 per share. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 annualized dividend and a dividend yield of 4.0%. The ex-dividend date of this dividend was Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio is 73.04%.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Positive Phase III interim topline results reported for izalontamab brengitecan (Iza‑bren) in previously treated unresectable locally advanced/metastatic triple‑negative breast cancer — the readout validates an ADC Bristol Myers licensed and could materially boost future revenue potential (deal carries >$8B long‑term economics that BMS has highlighted), which is likely the main driver lifting sentiment today. Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer
• Neutral Sentiment: Coverage pieces note BMY has lagged the Nasdaq over the last year, but Wall Street remains moderately optimistic — this frames today’s rally as driven more by idiosyncratic clinical news than by broad market leadership. Is Bristol-Myers Squibb Stock Underperforming the Nasdaq?
• Neutral Sentiment: Sector updates and analyst writeups (momentum/value profiles) are highlighting BMY as a top‑ranked momentum/value/dividend candidate for different investor styles — these stories can attract additional retail and income‑oriented flows but are not major catalysts by themselves. Bristol Myers Squibb (BMY) is a Top-Ranked Momentum Stock: Should You Buy?
• Neutral Sentiment: General pharma‑sector coverage and updates mention BMY among large‑cap players with deep late‑stage pipelines — supportive context but not a standalone catalyst. Bristol Myers Squibb (NYSE:BMY) Update Pharma Sector Developments
• Negative Sentiment: RBC Capital initiated coverage with a Sector Perform rating and a $60 price target (implying slight downside versus recent levels); that cautious initiation caps upside for some investors and may limit the size of gains if broader sentiment cools. RBC Capital Initiates Bristol Myers (BMY) with $60 Target

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.